A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

July 15, 2020

Conditions

Solid Tumors

Interventions

DRUG

RC48-ADC

Trial Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT02881138 - A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter